INTERVIEW: GtreeBNT Looks To Novelty, Deals To Become Dry Eye Player
Executive Summary
GtreeBNT is looking to challenge one of the biggest ophthalmology sectors through a novel dry eye syndrome drug with multiple mechanisms of action that the South Korean venture believes can help it carve a significant global niche, helped by international licensing deals.
You may also be interested in...
GtreeBNT Aims To Validate Business Model Via Licensing Deals
2017 may be a milestone year for GtreeBNT as it progresses its late clinical stage pipeline in the US for various high-need indications including glioblastoma, the South Korean bioventure’s CEO assuring investors that he expects to see “good results” in the near future as it seeks licensing deals for its assets.
Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support
South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.
Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback